Literature DB >> 25248380

Intratumor heterogeneity in hepatocellular carcinoma.

Juliane Friemel1, Markus Rechsteiner2, Lukas Frick2, Friederike Böhm2, Kirsten Struckmann2, Michèle Egger2, Holger Moch2, Mathias Heikenwalder3, Achim Weber4.   

Abstract

PURPOSE: Morphologic intratumor heterogeneity is well known to exist in hepatocellular carcinoma (HCC), but very few systematic analyses of this phenomenon have been performed. The aim of this study was to comprehensively characterize morphologic intratumor heterogeneity in HCC. Also, taken into account were well-known immunohistochemical markers and molecular changes in liver cells that are considered in proposed classifications of liver cell neoplasms or discussed as molecular therapeutic targets. EXPERIMENTAL
DESIGN: In HCC of 23 patients without medical pretreatment, a total of 120 tumor areas were defined. Analyzed were cell and tissue morphology, expression of the liver cell markers cytokeratin (CK)7, CD44, α-fetoprotein (AFP), epithelial cell adhesion molecule (EpCAM), and glutamine synthetase (GS) along with mutations of TP53 and CTNNB1, assayed by both Sanger and next-generation sequencing.
RESULTS: Overall, intratumor heterogeneity was detectable in the majority of HCC cases (20 of 23, 87%). Heterogeneity solely on the level of morphology was found in 6 of 23 cases (26%), morphologic heterogeneity combined with immunohistochemical heterogeneity in 9 of 23 cases (39%), and heterogeneity with respect to morphologic, immunohistochemical, and mutational status of TP53 and CTNNB1 in 5 of 23 cases (22%).
CONCLUSIONS: Our findings demonstrate that intratumor heterogeneity represents a challenge for the establishment of a robust HCC classification and may contribute to treatment failure and drug resistance in many cases of HCC. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25248380     DOI: 10.1158/1078-0432.CCR-14-0122

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  108 in total

Review 1.  Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Authors:  Renumathy Dhanasekaran; Jean-Charles Nault; Lewis R Roberts; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2018-11-04       Impact factor: 22.682

2.  Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients.

Authors:  Zhe-Zhen Li; Long Bai; Feng Wang; Zi-Chen Zhang; Fang Wang; Zhao-Lei Zeng; Jun-Bo Zeng; Dong-Sheng Zhang; Feng-Hua Wang; Zhi-Qiang Wang; Yu-Hong Li; Jian-Yong Shao; Rui-Hua Xu
Journal:  Med Oncol       Date:  2016-06-06       Impact factor: 3.064

Review 3.  Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice.

Authors:  Kornelius Schulze; Jessica Zucman-Rossi
Journal:  Hepat Oncol       Date:  2015-07-27

Review 4.  Hepatocellular Carcinoma: Etiology and Current and Future Drugs.

Authors:  Aastha Jindal; Anusha Thadi; Kunwar Shailubhai
Journal:  J Clin Exp Hepatol       Date:  2019-01-25

5.  Histological heterogeneity in primary and metastatic classic combined hepatocellular-cholangiocarcinoma: a case series.

Authors:  Claudio De Vito; Debashis Sarker; Paul Ross; Nigel Heaton; Alberto Quaglia
Journal:  Virchows Arch       Date:  2017-07-13       Impact factor: 4.064

6.  Hepatocyte selection medium-enriched hepatocellular carcinoma cells are positive for α-fetoprotein and CD44.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Naoki Ishige
Journal:  Oncol Lett       Date:  2017-05-24       Impact factor: 2.967

Review 7.  Radiomics of hepatocellular carcinoma.

Authors:  Sara Lewis; Stefanie Hectors; Bachir Taouli
Journal:  Abdom Radiol (NY)       Date:  2021-01

8.  Outcomes of Salvage Liver Transplantation and Re-resection/Radiofrequency Ablation for Intrahepatic Recurrent Hepatocellular Carcinoma: A New Surgical Strategy Based on Recurrence Pattern.

Authors:  Xiaoyun Zhang; Chuan Li; Tianfu Wen; Wei Peng; Lunan Yan; Jiayin Yang
Journal:  Dig Dis Sci       Date:  2017-12-14       Impact factor: 3.199

9.  Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma.

Authors:  Elizabeth L Yanik; Srinath Chinnakotla; Sally K Gustafson; Jon J Snyder; Ajay K Israni; Dorry L Segev; Eric A Engels
Journal:  Liver Transpl       Date:  2016-05       Impact factor: 5.799

10.  Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing.

Authors:  Meng Duan; Junfeng Hao; Sijia Cui; Daniel L Worthley; Shu Zhang; Zhichao Wang; Jieyi Shi; Longzi Liu; Xiaoying Wang; Aiwu Ke; Ya Cao; Ruibin Xi; Xiaoming Zhang; Jian Zhou; Jia Fan; Chong Li; Qiang Gao
Journal:  Cell Res       Date:  2018-01-12       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.